This group of pharmaceuticals made a breakthrough in the field of heart failure (HF) when clinical trials demonstrated that SGLT2 inhibitors independently reduce cardiovascular death and hospitalization for HF in diabetic and non-diabetic patients [5, 6]. This evidence concerns the gene SLC5A2 and hydrops fetalis.